Glycaemic variability and hypoglycaemia are associated with C-peptide levels in insulin-treated type 2 diabetes.

CONCLUSION: - In patients with insulin-treated T2D, low levels of C-peptide are associated with greater glycaemic variability and higher risk of hypoglycaemia, suggesting that C-peptide levels should be taken into consideration when optimalizing insulin treatment and assessing hypoglycaemia risk. PMID: 30796973 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30796973?dopt=Abstract

Source: Diabetes and Metabolism - February 20, 2019 Category: Endocrinology Authors: Christensen MB, Gæde P, Hommel E, Gotfredsen A, Nørgaard K Tags: Diabetes Metab Source Type: research